Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Ki-67 antigen expression in the mammary epithelium of female rats in persistent estrus treated with raloxifene
G. V. de Sousa1, C. S. Borges1, P. V. Lopes-Costa1, D. R. Costa-Silva1, S. F. Lopes-Dias1, A. C. P. Nazário Nazário2, A. P. Alencar3, B. B. da Silva1,*
1 Department of Gynecology, Federal University of Piauí, Teresina, Piauí
1 Sao Paulo
2 Department of Gynecology, Federal University of Sao Paulo
3 Department of Statistics, University of São Paulo, São Paulo (Brazil)
Eur. J. Gynaecol. Oncol. 2015, 36(6), 694–697; https://doi.org/10.12892/ejgo2720.2015
Published: 10 December 2015
Objective: To evaluate Ki-67 antigen expression in the mammary epithelium of female rats in persistent estrus treated with raloxifene. Materials and Methods: Forty-one Wistar-Hannover rats in persistent estrus induced by1.25 mg of testosterone propionate were randomly divided into two groups: Group A (control, n=21) in which the animals received only the vehicle (propylene glycol) and Group B (experimental, n=20) in which the rats received 750 μg/day of raloxifene by gavage. After 21 days of treatment, all the animals were sacrificed and the first pair of abdominal-inguinal mammary glands was extirpated and fixed in 10% buffered formalin to investigate Ki-67 expression by immunohistochemistry. The data were analysed using Student’s t-test (p < 0.05). Results: The percentage of Ki- 67-stained nuclei per 500 cells in the mammary epithelium was 42.33±6.18 and 15.51±3.71 [mean ± standard error of the mean (SEM)] in the control and experimental groups, respectively (p < 0.001). Conclusion: Raloxifene treatment significantly reduced Ki-67 expression in the mammary epithelium of rats in persistent estrus.